nach oben

Current Urology Reports

Erschienen in:

01.09.2016 | Men’s Health (A Dabaja, Section Editor)

Peyronie’s Disease: Intralesional Therapy and Surgical Intervention

verfasst von: Louis A. Aliperti, Akanksha Mehta

Erschienen in: Current Urology Reports | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Peyronie’s disease is a collagen wound healing disorder of the penis that negatively affects the quality of life of afflicted men. According to the 2015 AUA Consensus Guidelines on Peyronie’s Disease, minimally invasive intralesional therapies and surgical intervention form the basis of contemporary therapy for this disorder. These therapeutic options, along with selected portions of the guidelines, are explored in this review.

Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, et al. Epidemiology of Peyronie’s disease. Int J Impot Res. 2002;14(5):379–83. doi:10.1038/sj.ijir.3900863.CrossRefPubMed

Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodosio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie’s disease in men over 50-y-old from Southern Brazil. Int J Impot Res. 2001;13(5):291–3.CrossRefPubMed

Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88(7):727–30.CrossRefPubMed

Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 Pt 1):2350–3.CrossRefPubMed

El-Sakka AI, Tayeb KA. Peyronie’s disease in diabetic patients being screened for erectile dysfunction. J Urol. 2005;174(3):1026–30. doi:10.1097/01.ju.0000170231.51306.32.CrossRefPubMed

Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010;7(3):1254–61. doi:10.1111/j.1743-6109.2009.01655.x.CrossRefPubMed

Nugteren HM, Nijman JM, de Jong IJ, van Driel MF. The association between Peyronie’s and Dupuytren’s disease. Int J Impot Res. 2011;23(4):142–5. doi:10.1038/ijir.2011.18.CrossRefPubMed

Devine Jr CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol. 1997;157(1):285–90.CrossRefPubMed

Tal R, Mulhall JP. Intracavernosal injections and fibrosis: myth or reality? BJU Int. 2008;102(5):525–6. doi:10.1111/j.1464-410X.2008.07738.x.CrossRefPubMed

10.

Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175(6):2115–8. doi:10.1016/S0022-5347(06)00270-9. discussion 8.CrossRefPubMed

11.

Greenfield JM, Levine LA. Peyronie’s disease: etiology, epidemiology and medical treatment. Urol Clin North Am. 2005;32(4):469–78. doi:10.1016/j.ucl.2005.08.011. vii.CrossRefPubMed

12.

El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol. 1997;158(4):1391–4.CrossRefPubMed

13.

Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J Invest Dermatol. 1990;95(6 Suppl):75S–80S.CrossRefPubMed

14.

Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89–94. doi:10.3109/00365599109024539.CrossRefPubMed

15.

Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie’s disease. Int J Impot Res. 1999;11(4):207–12.CrossRefPubMed

16.••

Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394–8. doi:10.1016/S0022-5347(06)00517-9. Extremely important reference: This is the only randomized placebo controlled trial testing intralesional interferon administration.CrossRefPubMed

17.

Lacy 2nd GL, Adams DM, Hellstrom WJ. Intralesional interferon-alpha-2b for the treatment of Peyronie’s disease. Int J Impot Res. 2002;14(5):336–9. doi:10.1038/sj.ijir.3900867.CrossRefPubMed

18.

Kelly RB. Pathways of protein secretion in eukaryotes. Science. 1985;230(4721):25–32.CrossRefPubMed

19.

Askey DB, Herman IM. Computer-assisted analysis of the vascular endothelial cell motile response to injury. Comput Biomed Res. 1988;21(6):551–61.CrossRefPubMed

20.

Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie’s disease: a review. Int J Impot Res. 2002;14(5):324–8. doi:10.1038/sj.ijir.3900917.CrossRefPubMed

21.

Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620–6.CrossRefPubMed

22.

Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168(2):621–5. discussion 5–6.CrossRefPubMed

23.

Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522–4.PubMed

24.

Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467–71. doi:10.1007/s11255-009-9522-4.CrossRefPubMed

25.

Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468–73. doi:10.1111/j.1743-6109.2008.00814.x.CrossRefPubMed

26.

Dhillon S. Collagenase clostridium histolyticum: a review in Peyronie’s disease. Drugs. 2015;75(12):1405–12. doi:10.1007/s40265-015-0441-7.CrossRefPubMed

27.••

Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207. doi:10.1016/j.juro.2013.01.087. Extremely important reference: This is the phase 3 trial data for which FDA approval for Xiaflex was granted.CrossRefPubMed

28.

Inc. AP. US Prescribing Information. Auxilium Pharmaceuticals Inc. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125338s085s087s088lbl.pdf. Accessed 5/21/16 2016.

29.

Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745–53. doi:10.1016/j.juro.2015.05.098.CrossRefPubMed

30.

Carson 3rd CC, Sadeghi-Nejad H, Tursi JP, Smith TM, Kaufman GJ, Gilbert K, et al. Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int. 2015;116(5):815–22. doi:10.1111/bju.13120.CrossRefPubMed

31.

Mobley EM, Fuchs ME, Myers JB, Brant WO. Update on plication procedures for Peyronie’s disease and other penile deformities. Adv Urol. 2012;4(6):335–46. doi:10.1177/1756287212448224.CrossRef

32.

Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol. 2002;167(5):2066–9.CrossRefPubMed

33.

Ralph DJ, Al-kraa M, Pryor JP. The Nesbit operation for Peyronie’s disease: 16-year experience. J Urol. 1995;154(4):1362–3.CrossRefPubMed

34.

Levine LA, Burnett AL. Standard operating procedures for Peyronie’s disease. J Sex Med. 2013;10(1):230–44. doi:10.1111/j.1743-6109.2012.03003.x.CrossRefPubMed

35.

Gelbard MK. Relaxing incisions in the correction of penile deformity due to Peyronie’s disease. J Urol. 1995;154(4):1457–60.CrossRefPubMed

36.

Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Graft materials in Peyronie’s disease surgery: a comprehensive review. J Sex Med. 2007;4(3):581–95. doi:10.1111/j.1743-6109.2007.00461.x.CrossRefPubMed

37.

Lentz AC, Carson 3rd CC. Peyronie’s surgery: graft choices and outcomes. Curr Urol Rep. 2009;10(6):460–7.CrossRefPubMed

38.

Knoll LD, Furlow WL. Corporeal reconstruction and prosthetic implantation for impotence associated with non-dilatable corporeal cavernosal fibrosis. Acta Urol Belg. 1992;60(1):15–25.PubMed

39.

Hatzichristodoulou G. Partial plaque excision and grafting with collagen fleece in Peyronie disease. J Sex Med. 2016;13(2):277–81. doi:10.1016/j.jsxm.2015.12.011.CrossRefPubMed

40.

Hatzichristodoulou G, Gschwend JE, Lahme S. Surgical therapy of Peyronie’s disease by partial plaque excision and grafting with collagen fleece: feasibility study of a new technique. Int J Impot Res. 2013;25(5):183–7. doi:10.1038/ijir.2013.7.CrossRefPubMed

41.

Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med. 2008;5(9):2221–8. doi:10.1111/j.1743-6109.2008.00941.x. discussion 9–30.CrossRefPubMed

42.

Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie’s disease: a review. J Urol. 2003;169(4):1234–41. doi:10.1097/01.ju.0000053800.62741.fe.CrossRefPubMed

43.

Trost L, Wanzek P, Bailey G. A practical overview of considerations for penile prosthesis placement. Nat Rev Urol. 2016;13(1):33–46. doi:10.1038/nrurol.2015.270.CrossRefPubMed

44.

Garaffa G, Minervini A, Christopher NA, Minhas S, Ralph DJ. The management of residual curvature after penile prosthesis implantation in men with Peyronie’s disease. BJU Int. 2011;108(7):1152–6. doi:10.1111/j.1464-410X.2010.10023.x.CrossRefPubMed

45.

Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with Peyronie’s disease and drug-resistant erectile dysfunction: a single-center study. J Sex Med. 2010;7(11):3775–83. doi:10.1111/j.1743-6109.2010.01971.x.CrossRefPubMed

46.•

Chung PH, Scott JF, Morey AF. High patient satisfaction of inflatable penile prosthesis insertion with synchronous penile plication for erectile dysfunction and Peyronie’s disease. J Sex Med. 2014;11(6):1593–8. 10.1111/jsm.12530. Important reference: This paper explores combinging plication and IPP placement.CrossRefPubMed

47.•

Levine LA, Larsen SM. Surgical correction of persistent Peyronie’s disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015;12(1):259–64. doi:10.1111/jsm.12721. Important reference: This paper suggests collagenase administration is not a contraindication to surgical intervention.CrossRefPubMed

48.

LaRochelle JC, Levine LA. A Survey of primary-care physicians and urologists regarding Peyronie’s disease. J Sex Med. 2007;4(4 Pt 2):1167–73. doi:10.1111/j.1743-6109.2007.00537.x.CrossRefPubMed

Titel: Peyronie’s Disease: Intralesional Therapy and Surgical Intervention
verfasst von: Louis A. Aliperti
Akanksha Mehta
Publikationsdatum: 01.09.2016
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 9/2016
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-016-0622-2

Neu im Fachgebiet Urologie

22.04.2024 | Prostatakarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Peyronie’s Disease: Intralesional Therapy and Surgical Intervention

Abstract

Neu im Fachgebiet Urologie

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

Ct2 Bladder Cancer

Mesh Perforation into a Viscus in the Setting of Pelvic Floor Surgery—Presentation and Management

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage

Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy

Role of Abnormal Sperm Morphology in Predicting Pregnancy Outcomes

The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery

Neu im Fachgebiet Urologie

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Urologie